Amifostine: a radioprotector in locally advanced head and neck tumors.

  • Authors:
    • W Wagner
    • F J Prott
    • K G Schonekas
  • View Affiliations

  • Published online on: Tuesday, September 1, 1998
  • Pages: 1255-1262
  • DOI: 10.3892/or.5.5.1255

Abstract

Patients with locally advanced head and neck tumors were treated +/-amifostine (200 mg/m2, i.v.) before radiotherapy (5x 2 Gy, for 6 weeks). A significant decrease in side effects (p=0.034) using the oral assessment score and duration of mucositis (p=0.02) in the amifostine group was observed. Amifostine is feasible and effective, decreasing acute and late side effects in patients with head and neck tumors.
Journal Cover

September 1998
Volume 5 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

2013 Impact Factor: 2.191
Ranked #33/202 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wagner, W., Prott, F., & Schonekas, K. (1998). Amifostine: a radioprotector in locally advanced head and neck tumors.. Oncology Reports, 5(5), 1255-1262.
MLA
Wagner, Prott, and K G Schonekas. "Amifostine: a radioprotector in locally advanced head and neck tumors.." Oncology Reports Oncology Reports 5.5 (1998): 1255-1262.
Chicago
Wagner, Prott, and K G Schonekas. "Amifostine: a radioprotector in locally advanced head and neck tumors.." Oncology Reports Oncology Reports 5 no. 5 (1998): 1255-1262.